Institute of Hematology

Established in 1957, the Institute of Hematology and Blood Diseases Hospital (IH) is part of the CAMS/PUMC system. It is the national center for research and education in hematology and is also the largest treatment center for blood diseases in China. The State Key Laboratory of Experimental Hematology (SKLEH) and the National Stem Cell Engineering Technology & Research Center are housed in IH. The hospital is the top-ranked specialty hospital in both clinical care and scientific impact in the field of hematology in China. Currently, IH has 1,163 employees, 414 research projects, and has received research funding totaling about RMB300 million (US$44.9 million) in the last ten years.

Over the past several decades, IH has made many significant contributions in hematology research in China. Some examples include:

Isolation of a new dextran strain-selected from 1564 isolates between 1957 and 1958—that is still used today as blood plasma substitute.

Creation of the first domestic mouse strain in 1961, which set an important precedent for experimental studies of leukemia in China.

The first large-scale epidemiological investigation of leukemia, aplastic anemia, and other hematopoietic disorders in China.

Development of more than 200 monoclonal antibodies against human proteins, of which more than 60 were officially listed in the cluster of differentiation monoclonal antibody series by the International Meeting of Collaborative Groups on the Classification of Leukocyte Differentiation Antigens.

Pioneering use of homoharritonineas an effective chemotherapeutic agent in the treatment of acute myeloid leukemia (AML).
Development of an effective immune suppressive therapy for severe aplastic anemia (SAA).
Development of a stem cell treatment protocol for the management of ischemic ulcers.
Discovery of a new leukemia suppressor gene, SETD2, and its mutation in human acute leukemia.

As a comprehensive center for hematology, IH is committed to standardizing protocols for diagnosis and treatment, developing new technologies and methods for translational medicine in hematological malignancies, and advancing the field of hematology in China.